- What other names is Deanol known by?
- What is Deanol?
- How does Deanol work?
- Are there safety concerns?
- Are there any interactions with medications?
- Dosing considerations for Deanol.
2-Dimethyl Aminoethanol, 2-Dimethylaminoethanol, Acéglumate de Déanol, Acétamido-benzoate de Déanol, Benzilate de Déanol, Bisorcate de Déanol, Cyclohexylpropionate de Déanol, Déanol, Deanol Aceglumate, Deanol Acetamidobenzoate, Deanol Benzilate, Deanol Bisorcate, Deanol Cyclohexylpropionate, Deanol Hemisuccinate, Deanol Pidolate, Deanol Tartrate, Dimethylaminoethanol, Diméthylaminoéthanol, Dimethylaminoethanol Bitartrate, Dimethylethanolamine, DMAE, DMAE Bitartrate, Hémisuccinate de Déanol, Pidolate de Déanol.
Deanol is a chemical that is involved in a series of reactions that form acetylcholine, a chemical that is found in the brain and other areas of the body. Acetylcholine is a “neurotransmitter” that helps nerve cells communicate.
Deanol is used for treating attention deficit-hyperactivity disorder (ADHD), Alzheimer's disease, autism, and a movement disorder called tardive dyskinesia. It is also used for improving memory and mood; boosting thinking skills and intelligence; and increasing physical energy, oxygen efficiency, athletic performance, and muscle reflexes. It is also used for preventing aging or liver spots, improving red blood cell function, and extending life span.
Deanol is applied to the skin for reducing signs of aging, particularly loose or sagging skin.
Deanol was previously sold by Riker Laboratories as the prescription drug Deaner. It was prescribed for the management of children with behavior problems and learning difficulties. Deanol is not an approved food additive in the U.S., nor is it an orphan drug, as some advertising suggests.
Possibly Effective for...
Likely Ineffective for...
Insufficient Evidence to Rate Effectiveness for...
- Treating aging skin. There is some early evidence that applying a 3% deanol gel to facial skin can tighten sagging skin.
- Treating attention deficit-hyperactivity disorder (ADHD).
- Improving memory and mood.
- Improving intelligence and physical energy.
- Preventing aging or liver spots.
- Improving red blood cell function.
- Improving muscle reflexes.
- Increasing oxygen efficiency.
- Extending life span.
- Treating autism.
- Other conditions.
Deanol is needed to build the chemical choline. Having more choline in the body might increase the production of acetylcholine, which is involved in brain and nervous system function.
Deanol is POSSIBLY SAFE for most people when taken by mouth or applied to the skin.
When taken by mouth, deanol can cause constipation, itching, headache, drowsiness, insomnia, excitation, vivid dreams, confusion, depression, increased blood pressure, an increase in schizophrenia symptoms, and unwanted movements of the face and mouth.
Special Precautions & Warnings:Pregnancy and breast-feeding: Not enough is known about the use of deanol during pregnancy and breast-feeding. Stay on the safe side and avoid use.
Drying medications (Anticholinergic drugs)Interaction Rating: Minor Be cautious with this combination.Talk with your health provider.
Some drying medications are called anticholinergic drugs. Deanol might increase chemicals that can decrease the effects of these drying medications.
Medications for Alzheimer's disease (Acetylcholinesterase (AChE) inhibitors)Interaction Rating: Minor Be cautious with this combination.Talk with your health provider.
Deanol might increase a chemical in the body called acetylcholine. Medications for Alzheimer's called acetylcholinesterase inhibitors also increase the chemical acetylcholine. Taking deanol along with medications for Alzheimer's disease might increase effects and side effects of medications for Alzheimer's disease.
Various medications used for glaucoma, Alzheimer's disease, and other conditions (Cholinergic drugs)Interaction Rating: Minor Be cautious with this combination.Talk with your health provider.
Deanol might increase a chemical in the body called acetylcholine. This chemical is similar to some medications used for glaucoma, Alzheimer's disease, and other conditions. Taking deanol with these medications might increase the chance of side effects.
Some of these medications used for glaucoma, Alzheimer's disease, and other conditions include pilocarpine (Pilocar and others), and others.
The following doses have been studied in scientific research:
- For improving exercise performance: 300 to 2000 mg of deanol per day.
Natural Medicines Comprehensive Database rates effectiveness based on scientific evidence according to the following scale: Effective, Likely Effective, Possibly Effective, Possibly Ineffective, Likely Ineffective, and Insufficient Evidence to Rate (detailed description of each of the ratings).
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Health Solutions From Our Sponsors
Casey DE. Mood alterations during deanol therapy. Psychopharmacology (Berl) 1979;62:187-91. View abstract.
Cherkin A, Exkardt MJ. Effects of dimethylaminoethanol upon life-span and behavior of aged Japanese quail. J Gerontol 1977;32:38-45. View abstract.
Davies C, Maidment S, Hanley P, et al. Dimethylaminoethanol (DMAE). HSE. Risk assessment document; EH72/2;1997. (TOXLINE).
de Montigny C, Chouinard G, Annable L. Ineffectiveness of deanol in tardive dyskinesia: a placebo controlled study. Psychopharmacology (Berl) 1979;65:219-23. View abstract.
Ferris SH, Sathananthan G, Gershon S, et al. Senile dementia: treatment with deanol. J Am Geriatr Soc 1977;25:241-4. View abstract.
Fisman M, Mersky H, Helmes E. Double-blind trial of 2-dimethylaminoethanol in Alzheimer's disease. Am J Psychiatry 1981;138:970-2. View abstract.
George J, Pridmore S, Aldous D. Double blind controlled trial of deanol in tardive dyskinesia. Aust N Z J Psychiatry 1981;15:68-71. View abstract.
Haug BA, Holzgraefe M. Orofacial and respiratory tardive dyskinesia: potential side effects of 2-dimethylaminoethanol (deanol)? Eur Neurol 1991;31:423-5. View abstract.
Jus A, Villeneuve A, Gautier J, et al. Deanol, lithium and placebo in the treatment of tardive dyskinesia. A double-blind crossover study. Neuropsychobiology 1978;4:140-9. View abstract.
Lewis JA, Young R. Deanol and methylphenidate in minimal brain dysfunction. Clin Pharmacol Ther 1975;17:534-40. View abstract.
Lindeboom SF, Lakke JP. Deanol and physostigmine in the treatment of L-dopa-induced dyskinesias. Acta Neurol Scand 1978;58:134-8. View abstract.
McGrath JJ, Soares KVS. Cholinergic medication for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2000;(2):CD000207. View abstract.
Oettinger L Jr. Pediatric psychopharmacology. A review with special reference to deanol. Dis Nerv Syst 1977;38:25-31.
Osol A, Hoover JE, eds. Remington's Pharmaceutical Science, 15th ed. Easton, PA: Mack Publishing Company, 1975.
Penovich P, Morgan JP, Kerzner B, et al. Double-blind evaluation of deanol in tardive dyskinesia. JAMA 1978;239:1997-8. View abstract.
Pieralisi G, Ripari P, Vecchiet L. Effects of a standardized ginseng extract combined with dimethylaminoethanol bitartrate, vitamins, minerals, and trace elements on physical performance during exercise. Clin Ther 1991;13:373-82. View abstract.
Re O. 2-Dimethylaminoethanol (deanol): a brief review of its clinical efficacy and postulated mechanism of action. Curr Ther Res Clin Exp 1974;16:1238-42.
Sergio W. Use of DMAE (2-dimethylaminoethanol) in the induction of lucid dreams. Med Hypotheses 1988;26:255-7. View abstract.
Soares KV, McGrath JJ. The treatment of tardive dyskinesia- a systematic review and meta-analysis. Schizophr Res 1999;39:1-16; discussion 17-18. View abstract.
Stenback F, Weisburger JH, Williams GM. Effect of lifetime administration of dimethylaminoethanol on longevity, aging changes, and cryptogenic neoplasms in C3H mice. Mech Ageing Dev 1988;42:129-38. View abstract.
Uhoda I, Faska N, Robert C, et al. Split face study on the cutaneous tensile effect of 2-dimethylaminoethanol (deanol) gel. Skin Res Technol 2002;8:164-7. View abstract.